PDCD1 and nonpapillary renal cell carcinoma: In contrast to other solid tumors, tumor mutational burden and neoantigen load, which have been the commonly explored predictors for ICIs therapy, were not associated with clinical responses to PD-1 blockade in advanced ccRCC [4].